

# SECURITIES AND EXCHANGE COMMISSION

## FORM 8-K

Current report filing

Filing Date: **2009-01-26** | Period of Report: **2009-01-26**  
SEC Accession No. **0000835887-09-000001**

([HTML Version](#) on [secdatabase.com](http://secdatabase.com))

### FILER

#### **PROGENICS PHARMACEUTICALS INC**

CIK: **835887** | IRS No.: **133379479** | State of Incorpor.: **DE** | Fiscal Year End: **1231**  
Type: **8-K** | Act: **34** | File No.: **000-23143** | Film No.: **09545161**  
SIC: **2834** Pharmaceutical preparations

Mailing Address  
777 OLD SAW MILL RIVER  
ROAD  
TARRYTOWN NY 10591

Business Address  
777 OLD SAW MILL RIVER  
ROAD  
TARRYTOWN NY 10591  
9147892800

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 26, 2009

**Progenics Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

**000-23143**  
(Commission  
File Number)

**13-3379479**  
(IRS Employer  
Identification No.)

777 Old Saw Mill River Road, Tarrytown, New York  
(Address of principal executive offices)

Registrant's telephone number, including area code (914) 789-2800

10591  
(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), with which Progenics collaborates in the development and commercialization of RELISTOR<sup>®</sup>, has informed Progenics that global net sales of RELISTOR for the fourth quarter of 2008 were \$1.5 million, as compared to \$0.8 million in the third quarter of 2008. Wyeth began full promotion of RELISTOR in mid-August, under a program that included sales detailing, the offering of early experience trial kits and company-directed educational programs. Global net sales for 2008, which commenced in June, totaled \$4.4 million.

RELISTOR is the first drug in a novel class for a completely new therapeutic use – opioid-induced constipation. The approved indication for RELISTOR addresses the needs of individuals with advanced illness receiving palliative care. Ongoing clinical studies have the goal of expanding the use of RELISTOR in other patient settings.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MCKINNEY

Officer, Senior Vice President,  
and Treasurer

Date: January 26, 2009

PROGENICS PHARMACEUTICALS, INC.  
By: /s/ ROBERT A.

Robert A. McKinney  
Chief Financial  
Finance & Operations